Literature DB >> 1721450

Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases.

N L Nikolaidis1, K Abu-Elmagd, A W Thomson, H R Rilo, W D Irish, D H Van Thiel, J J Fung, T E Starzl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1721450      PMCID： PMC2966018     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  5 in total

1.  Transplantation.

Authors:  T E Starzl; J J Fung
Journal:  JAMA       Date:  1990-05-16       Impact factor: 56.272

2.  A highly sensitive method to assay FK-506 levels in plasma.

Authors:  K Tamura; M Kobayashi; K Hashimoto; K Kojima; K Nagase; K Iwasaki; T Kaizu; H Tanaka; M Niwa
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

Review 3.  Management of patients and side effects during cyclosporine therapy for cutaneous disorders.

Authors:  M S Fradin; C N Ellis; J J Voorhees
Journal:  J Am Acad Dermatol       Date:  1990-12       Impact factor: 11.527

4.  Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis.

Authors:  B V Jegasothy; C D Ackerman; S Todo; J J Fung; K Abu-Elmagd; T E Starzl
Journal:  Arch Dermatol       Date:  1992-06

5.  Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial.

Authors:  C N Ellis; M S Fradin; J M Messana; M D Brown; M T Siegel; A H Hartley; L L Rocher; S Wheeler; T A Hamilton; T G Parish
Journal:  N Engl J Med       Date:  1991-01-31       Impact factor: 91.245
  5 in total
  1 in total

Review 1.  Tacrolimus for the management of psoriasis: clinical utility and place in therapy.

Authors:  Nina Malecic; Helen Young
Journal:  Psoriasis (Auckl)       Date:  2016-12-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.